Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 17 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide... January 14, 2022 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... August 17, 2020 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Load more HOT NEWS Is there a future without Pap testing? Study Finds Possible New Treatment for Metastatic Breast Cancer That Has... Mom Is Warning Other Parents After Her Son Was Bit By... What to Know About Exercising During Prostate Cancer: An Expert Q&A
